Saturday in Hyderabad came to the first lot of the Russian vaccine Sputnik V, the 3rd to be used in India, after Covishield and Covaxin.

The vaccinations come at a time of fatal coronavirus second wave ravages in the world. In the last 24 hours, coronavirus cases in the country reported 4.01.993 new infections. It has recorded 3,523 deaths.

“First batch of SputnikV vaccine arrives in Hyderabad, India! That’s the same day the country starts mass COVID vaccination drive covering its entire adult population. Let’s jointly defeat this pandemic. Together we are stronger,” a tweet posted from the official Twitter handle of Sputnik V.

The Central Board of Indirect Taxes and Customs (CBIC), in a tweet, said that Hyderabad customs expedited the clearance of the COVID-19 vaccine imported from Russia.

The Sputnik-V vaccine will strengthen India’s pandemic defenses. This third alternative would increase our vaccine capability while still speeding up our vaccination campaign. This is the first consignment of 1.5 lakh Sputnik-V vaccine doses, with millions more on the way  In a claim, the MEA said.

“The Sputnik V vaccine has one of the highest efficacy rates in the world, and it can also protect against current COVID-19 strains. Its local development is set to begin soon, with a goal of increasing to 850 million doses per year over time “The Russian Ambassador to India said this.

In Hyderabad, we got 1,50,000 doses of the Sputnik V vaccine today. After obtaining the necessary regulatory approvals, the vaccine will be available in a few weeks. “At that time, the price will be revealed,” said Deepak Sapra, CEO of Dr. Reddy’s Laboratories.

Dr. Reddy was awarded the delivery rights for the first 100 million doses in India, which were later increased to 125 million.

Dr. Reddy’s Laboratories, which has secured clearance from the Indian drug regulator for exclusive emergency use of Sputnik V, partnered with the Russian Direct Investment Fund (RDIF) to perform clinical trials of the vaccine in September.

In international markets, the two-dose vaccine produced by Russia’s Gamaleya Institute costs less than $10 an injection.